Increase Driven by Liver Cancer Development in Baby Boomers
HCV is the most common blood-borne infection and cause of liver disease requiring transplantation in the U.S., chronically infecting more than one percent of Americans. Previous studies show that among patients living with chronic HCV, 10% to 20% will develop cirrhosis and up to 5% will progress to liver cancer (hepatocellular carcinoma; HCC). Further evidence implicates HCV as the primary risk factor for developing HCC in up to 47% of cases of patients with HCC.
The peak U.S. HCV prevalence of 4% occurred in those born in 1940 through 1965, who were 20 to 30 years of age during 1979 to 1989, when HCV infection risk was at its highest. As this population ages, Davis et al. project that between 2000 and 2030 cirrhosis in patients with HCV will increase two-fold, from 472,000 to 879,000. Moreover, Wise et al. suggests HCV-related deaths will increase in Americans 55 to 64 years of age by 2004.
"The dire projections in HCV complications spurred our investigation of age-specific trends in liver transplantation demand," said lead author Dr. Scott Biggins with the University of Colorado School of Medicine in Aurora, Colo. For the present study, researchers identified all adult liver transplant candidates who were registered with the Organ Procurement and Transplantation Network (OPTN) between 1995 and 2010. Patients were then classified with the diagnosis of HCV, with or without HCC.
Results show there were 126,862 new candidates for first liver transplant registered with OPTN, with 41% of these having HCV. Candidates were categorized by birth year and found that the highest HCV frequency (in decreasing order) were those born in 1951-1955, 1956-1960, 1946-1950, and 1941-1945. These four birth groups represent 81% of all new liver transplant registrants with HCV.
Furthermore, findings indicate that between 2000 and 2010 there was a four-fold increase in new transplant candidates with HCV and HCC in the 1941 to 1960 birth cohorts. The authors anticipate an increase in the proportion of new registrants, 60 years and older, with HCV will have liver cancer.
"Over the coming decade the aging of those infected with HCV will challenge the transplant community to reconsider current treatment plans given the projected increase in liver transplantation demand, particularly from patients with HCV and liver cancer," concludes Dr. Biggins. "With the aging of the population of patients with HCV, many of these patients may not be healthy enough for transplantation and the number of liver transplants in patients with HCV may decrease."
This study was funded in part by grants from the National Center for Research Resources, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Agency for Healthcare Research and Quality.
This study is published in Liver Transplantation. Media wishing to receive a PDF of the article may contact email@example.com
Full citation: "Projected Future Increase in Aging HCV-Infected Liver Transplant Candidates: A Potential Effect of HCC." Scott W. Biggins, Kiran M. Bambha, Norah A. Terrault, John Inadomi, Stephen Shiboski, Jennifer L. Dodge, Jane Gralla, Hugo R. Rosen and John P. Roberts. Liver Transplantation; (DOI: 10.1002/lt.23551) Print Issue Date: December, 2012.
About the Journal:
Liver Transplantation is published by Wiley on behalf of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Since the first application of liver transplantation in a clinical situation was reported more than twenty years ago, there has been a great deal of growth in this field and more is anticipated. As an official publication of the AASLD and the ILTS, Liver Transplantation delivers current, peer-reviewed articles on surgical techniques, clinical investigations and drug research - the information necessary to keep abreast of this evolving specialty. For more information, please visit http://wileyonlinelibrary.com/
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
For advertising and promotion on www.HealthNewsDigest.com please contact Mike McCurdy: tvmike13@HealthNewsDigest.com or 877-634-9180HealthNewsDigest.com is syndicated worldwide, to thousands of journalists in all media, and health-related websites. www.HealthNewsDigest.com